Dana Pizzuti Sells 14,375 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) insider Dana Pizzuti sold 14,375 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $44.47, for a total value of $639,256.25. Following the sale, the insider now directly owns 27,786 shares of the company’s stock, valued at approximately $1,235,643.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dana Pizzuti also recently made the following trade(s):

• On Wednesday, March 20th, Dana Pizzuti sold 15,089 shares of Crinetics Pharmaceuticals stock. The stock was sold at an average price of $44.06, for a total value of $664,821.34.

Crinetics Pharmaceuticals Price Performance

Shares of CRNX stock opened at $43.01 on Friday. The stock has a market cap of $2.99 billion, a P/E ratio of -11.62 and a beta of 0.63. Crinetics Pharmaceuticals, Inc. has a one year low of $15.76 and a one year high of $49.58. The stock has a fifty day moving average price of $42.35 and a 200 day moving average price of $35.99.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its earnings results on Wednesday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 52.93% and a negative net margin of 4,223.27%. The firm’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.84) earnings per share. Equities research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.34 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Quarry LP acquired a new position in Crinetics Pharmaceuticals during the fourth quarter worth $36,000. China Universal Asset Management Co. Ltd. raised its stake in Crinetics Pharmaceuticals by 98.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,403 shares of the company’s stock worth $42,000 after acquiring an additional 695 shares in the last quarter. AJOVista LLC acquired a new position in Crinetics Pharmaceuticals during the fourth quarter worth $58,000. Tower Research Capital LLC TRC raised its stake in Crinetics Pharmaceuticals by 109.9% during the first quarter. Tower Research Capital LLC TRC now owns 1,927 shares of the company’s stock worth $31,000 after acquiring an additional 1,009 shares in the last quarter. Finally, Osaic Holdings Inc. raised its stake in Crinetics Pharmaceuticals by 382.4% during the second quarter. Osaic Holdings Inc. now owns 2,412 shares of the company’s stock worth $43,000 after acquiring an additional 1,912 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CRNX shares. Robert W. Baird upped their target price on Crinetics Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. JMP Securities reissued a “market outperform” rating and issued a $80.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Thursday, March 28th. Oppenheimer increased their price objective on Crinetics Pharmaceuticals from $54.00 to $55.00 and gave the company an “outperform” rating in a research report on Wednesday, March 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Tuesday, March 19th. Finally, Jefferies Financial Group began coverage on Crinetics Pharmaceuticals in a research report on Thursday, December 21st. They issued a “hold” rating and a $35.00 price objective for the company. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $54.17.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.